The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis

Background: Recent studies have showed that nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce the risk of several types of cancer. However, epidemiological evidence of the association between NSAIDs intake and the risk of hepatocellular carcinoma (HCC) remains controversial

[1]  E. Kang,et al.  Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case‐control study , 2017, International journal of cancer.

[2]  Lijing L. Yan,et al.  Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis , 2016, Oncotarget.

[3]  Lequn Li,et al.  Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival , 2016, World journal of gastroenterology.

[4]  S. Bojesen,et al.  Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population , 2016, International journal of cancer.

[5]  Z. Ren,et al.  Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis. , 2016, American journal of cancer research.

[6]  C. Su.  Hepatobiliary cancer: All efforts for one goal. , 2016, Cancer letters.

[7]  J. Li,et al.  Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis , 2016, Archives of medical science : AMS.

[8]  Tzeng-Ji Chen,et al.  Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection , 2016, Annals of Surgical Oncology.

[9]  Jie Chen,et al.  Associations of NSAID and paracetamol use with risk of primary liver cancer in the Clinical Practice Research Datalink. , 2016, Cancer epidemiology.

[10]  H. Saitsu,et al.  A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment , 2016, Hepatology International.

[11]  Jie Su,et al.  COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells , 2015, Medicine.

[12]  L. Hou,et al.  NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project , 2015, Cancer Prevention Research.

[13]  D. Vyas,et al.  Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies. , 2015, World journal of gastroenterology.

[14]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[15]  J. Stubbs,et al.  Reversing the Effects of Antiplatelet Agents in the Setting of Intracranial Hemorrhage , 2015, Journal of intensive care medicine.

[16]  Xiangyi Zheng,et al.  Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk , 2014, World Journal of Surgical Oncology.

[17]  U. Nöthlings,et al.  Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer , 2014, Hepatology.

[18]  U. Vogel,et al.  Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer , 2014, Alimentary pharmacology & therapeutics.

[19]  T. Burnouf,et al.  Platelet–Cancer Interactions , 2014, Seminars in Thrombosis & Hemostasis.

[20]  K. E. Visser,et al.  Cancer: Inflammation lights the way to metastasis , 2014, Nature.

[21]  E. Elinav,et al.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.

[22]  A. Yamauchi,et al.  A Meta-Analysis of PTGS1 and PTGS2 Polymorphisms and NSAID Intake on the Risk of Developing Cancer , 2013, PloS one.

[23]  Xuedong Li,et al.  Use of Nonsteroidal Anti-Inflammatory Drugs and Bladder Cancer Risk: A Meta-Analysis of Epidemiologic Studies , 2013, PloS one.

[24]  T. Pandita,et al.  The Role of Inflammatory Pathways in Cancer-Associated Cachexia and Radiation Resistance , 2013, Molecular Cancer Research.

[25]  N. Freedman,et al.  Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. , 2012, Journal of the National Cancer Institute.

[26]  Jaw-Town Lin,et al.  Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. , 2012, JAMA.

[27]  Shahid A. Khan,et al.  A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). , 2012, Journal of hepatology.

[28]  M. Thun,et al.  Daily aspirin use and cancer mortality in a large US cohort. , 2012, Journal of the National Cancer Institute.

[29]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[30]  Chun-Yuh Yang,et al.  Statin Use and the Risk of Liver Cancer: A Population-Based Case–Control Study , 2011, The American Journal of Gastroenterology.

[31]  Wenjing Tian,et al.  Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer , 2010, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[32]  E. El-Omar,et al.  Cancer and Inflammation: Promise for Biologic Therapy , 2010, Journal of immunotherapy.

[33]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[34]  P. Malfertheiner,et al.  Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors , 2009, Digestive Diseases.

[35]  C. Abnet,et al.  Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis , 2009, British Journal of Cancer.

[36]  M. Etminan,et al.  Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. , 2008, Journal of the National Cancer Institute.

[37]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[38]  P. Schirmacher,et al.  Differential expression of E‐prostanoid receptors in human hepatocellular carcinoma , 2008, International journal of cancer.

[39]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[40]  M. Cervello,et al.  Cyclooxygenases in hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[41]  C. Tripodo,et al.  The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. , 2006, International journal of molecular medicine.

[42]  B. Cryer.  Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. , 2005, The New England journal of medicine.

[43]  E. Ricciotti,et al.  Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells , 2003, British journal of pharmacology.

[44]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[45]  N. Chalasani,et al.  Screening for hepatocellular carcinoma in patients with advanced cirrhosis , 1999, American Journal of Gastroenterology.

[46]  William L. Smith,et al.  Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2* , 1996, The Journal of Biological Chemistry.

[47]  G. Sethi,et al.  Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. , 2013, Biochimica et biophysica acta.

[48]  K. Sarinc.  From Cirrhosis to Hepatocellular Carcinoma : New Molecular Insights on Inflammation and Cellular Senescence , 2013 .

[49]  D. McMillan,et al.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.

[50]  K. Kerlikowske,et al.  Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. , 2003, Gastroenterology.

[51]  S. Shapiro,et al.  Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[52]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[53]  S Greenland,et al.  Quantitative methods in the review of epidemiologic literature. , 1987, Epidemiologic reviews.

[54]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.